Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $186.0552W HIGH $282.15
Volume
641.43 K
Value Traded
107.65 M
Short % Float
6.1%
-0.95%Week
-15.78%1 Month
-14.95%3 Month
+0.52%6 Month
+78.26%5 Year
+1,049.07%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.99 B
EPS (TTM)
9.40
P/E Ratio
24.24
Ent. Value
13.88 B
Total Shares
65.78 M
Float Shares
64.91 M
Insiders
1.16%
Institutions
102.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ASND Catalyst Timeline
Dated clinical, regulatory and corporate events for Ascendis Pharma A/S
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ascendis Pharma A/S
371Total events
14Upcoming
101Tier-1 (high impact)
2014 to 2030Coverage
Upcoming catalysts 2
Event history 50
●Corporate ApprovalCorporate
Board of Directors authorized $400 million share repurchase program
▲Partnership / LicenseCorporate
Termination of Novo Nordisk collaboration; rights to TransCon metabolic/cardiovascular products revert to Ascendis
metabolic and cardiovascular diseases, including obesitysource ↗
▲Oral PresentationNavepegritideApprovedPresentation
Week 52 reACHin sentinel cohort infant data presented at ESPE 2026
achondroplasiasource ↗
▲Full ResultsNavepegritideApprovedClinical Data
Week 52 data from open-label sentinel cohort of reACHin Trial
achondroplasiasource ↗
▲Long Term DataNavepegritideApprovedClinical Data
Week 52 data from open-label sentinel cohort of reACHin Trial
achondroplasiasource ↗
◆Oral PresentationNavepegritideApprovedPresentation
Podium presentation of first sentinel cohort data from pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia
achondroplasiasource ↗
●Poster PresentationPresentation
Poster: Listening to the Patient Voice: Understanding and Assessing the Impact of Hypoparathyroidism on the Daily Lives of Adolescents
hypoparathyroidismsource ↗
●Poster PresentationLonapegsomatropinApprovedPresentation
Poster: HighLiGHts Phase 3 Trial Design: Lonapegsomatropin in Children with Short Stature or Growth Failure
short stature or growth failure due to Turner Syndrome, SHOX Deficiency, Small for Gestational Age, or Idiopathic Short Staturesource ↗
▲License DisputeYUVIWELApprovedIP / Competition
Binding term sheet for global settlement and license agreement with BioMarin
achondroplasiasource ↗
◆Oral PresentationNavepegritideApprovedPresentation
Oral presentation of Week 104 data from ApproaCH Trial at ISDS 2026
achondroplasiasource ↗
◆Poster PresentationNavepegritideApprovedPresentation
Poster presentation on injection site reactions at ISDS 2026
achondroplasiasource ↗
▲Enrollment CompleteYUVIWELApprovedTrial
Completed target enrollment for pivotal reACHin Trial
achondroplasiasource ↗
▲Long Term DataNavepegritideApprovedClinical Data
Week 78 COACH Trial data showed sustained efficacy
achondroplasiasource ↗
▲Full ResultsNavepegritideApprovedClinical Data
COACH Week 78 topline results for TransCon CNP + TransCon hGH combination therapy
achondroplasiasource ↗
▲Enrollment CompleteNavepegritideApprovedTrial
Completed target enrollment for pivotal reACHin trial
achondroplasiasource ↗
◆Enrollment CompleteYUVIWELApprovedTrial
Enrollment completion anticipated for reACHin trial in infants with achondroplasia
achondroplasia (infants)source ↗
▲Oral PresentationNavepegritideApprovedPresentation
Week 104 radiographic data presented at ICCBH 2026
achondroplasiasource ↗
◆EU MAA SubmissionNavepegritideApprovedEx-US Regulatory
MAA under review by EMA
achondroplasiasource ↗
▲Quarterly UpdateYUVIWELApprovedCorporate
YUVIWEL U.S. launch update: >170 patient enrollments through June 30, 2026
achondroplasiasource ↗
◆Oral PresentationNavepegritideApprovedPresentation
Oral presentation of Week 104 data from ApproaCH Trial showing improvements in lower-extremity alignment
achondroplasiasource ↗
◆Late-BreakerNavepegritideApprovedPresentation
Late-breaking poster of Week 52 data from COACH Trial of combination therapy with TransCon CNP and TransCon hGH
achondroplasiasource ↗
●Poster PresentationPresentation
Poster on estimating global birth prevalence of achondroplasia
achondroplasiasource ↗
◆Oral PresentationNavepegritideApprovedPresentation
52-Week Results from Phase 2 COACH Trial: Navepegritide Combined with Lonapegsomatropin
achondroplasiasource ↗
◆Poster PresentationPalopegteriparatideApprovedPresentation
156-Week Results: Palopegteriparatide Enhances Work Functioning and Productivity in Chronic Hypoparathyroidism
hypoparathyroidismsource ↗
◆Poster PresentationPresentation
Global Prevalence Estimates for Post-Surgical and Non-Surgical Chronic Hypoparathyroidism: Systematic Literature Review and Meta-Analysis
hypoparathyroidismsource ↗
◆Poster PresentationLonapegsomatropinApprovedPresentation
Safety and Effectiveness of Lonapegsomatropin in SkybriGHt Registry: First 100 Patients with 2 Years Follow-Up
pediatric growth hormone deficiencysource ↗
▲Full ResultsClinical Data
Week 182 data from Phase 3 PaTHway Trial showing sustained efficacy and safety
hypoparathyroidismsource ↗
●Oral PresentationPresentation
Slide presentation with Week 182 data made available on investor relations website
hypoparathyroidismsource ↗
◆Oral PresentationPalopegteriparatideApprovedPresentation
Final Results of Phase 3 PaTHway Trial in Adults with Hypoparathyroidism
hypoparathyroidismsource ↗
▲PRV SoldDesignation
Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million
▲Full ResultsLonapegsomatropinApprovedClinical Data
Week 52 data from Phase 2 New InsiGHTS Trial in Turner syndrome
Turner syndromesource ↗
▼Program DiscontinuationCorporate
Discontinued internal development of TransCon IL-2 β/γ in Oncology
oncologysource ↗
▲Subgroup AnalysisNavepegritideApprovedClinical Data
New 2-year data from subgroup of children ≥5 years in ApproaCH trial
achondroplasiasource ↗
◆EU MAA SubmissionYUVIWELApprovedEx-US Regulatory
EMA MAA for YUVIWEL under review
achondroplasiasource ↗
▲Enrollment MilestoneYUVIWELApprovedTrial
More than 60 unique patient enrollments for YUVIWEL since launch
achondroplasiasource ↗
▲Orphan Drug DesignationYUVIWELApprovedDesignation
YUVIWEL granted orphan drug exclusivity by FDA
achondroplasiasource ↗
▲Product LaunchYUVIWELApprovedPost-Market
YUVIWEL commercially available in the U.S.
achondroplasiasource ↗
Past FDA Catalysts and PDUFA Decisions
How ASND actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-27 | TransCon CNP (navepegritide) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$2.6B
Pipeline Value
$3.4B
Commercial Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 15%
Mid Cap(rank 99 of 655)
Percentile Rank
Ascendis Pharma A/S carries a moderate pipeline score (51/100), with $3.1B risk-adjusted pipeline value, led by Once weekly of TransCon hGH in Growth Hormone Deficiency, Pediatric (Phase 3).
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from EUR to USD, to Dec 2025; product lines from the latest annual filing) Revenue $821.2M x 4.2 = $3.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| YORVIPATH® | $544M | - | - |
| SKYTROFA® | $235M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Once weekly of TransCon hGH Small moleculeCompletedNCT02781727 | Growth Hormone Deficiency, Pediatric | Phase 3 | COMPLETED | 162 | Jan 17, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every ASND program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TransCon CNP Priority | achondroplasia | 2026-08-25 | durable improvements in height; improvements in lower-extremity alignment; improvements in body proportionality; improvements in spinal canal dimensions; improvements in muscle function; improvements in physical functioning; safety and tolerability profile similar to placebo; low rate of injection site reactionsRead More | Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bodenhoff MadsOfficer (SVP & PAO) | Option | 3,000 3,000 held | $110.00 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ASND
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 8.5 % (3.7 %) | 69.01 M | 258.74 K | 1.33% ( 3.41 K) |
ASND Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ASND ranks across every disease it competes in
Competitive Position is a premium feature
See how ASND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialASND News
-ASND
Sep 14, 2026▼ -9.5%on this news
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Ascendis Pharma has announced it will regain exclusive rights to develop TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows the termination of its collaboration with Novo Nordisk. Ascendis plans to initiate multiple new programs, including advancing once-monthly TransCon Semaglutide as a treatment for obesity and type 2 diabetes.
Read more →-ASND
Sep 14, 2026▼ -9.5%on this news
Ascendis Announces Planned $400 Million Share Repurchase Program
Ascendis Pharma A/S has announced a $400 million share repurchase program authorized by its Board of Directors. The program allows for repurchases through various methods, depending on market conditions. This initiative reflects the company's confidence in its financial standing and aims to enhance shareholder value.
Read more →-ASND
Sep 9, 2026First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Ascendis Pharma presented positive Week 52 data from the reACHin Trial for TransCon CNP, showing stabilization or improvement in foramen magnum stenosis and enhanced linear growth in infants with achondroplasia. The treatment was well tolerated, with no significant adverse events reported. The results suggest that early intervention with TransCon CNP could effectively address growth limitations and medical complications associated with the condition.
Read more →-ASND
Sep 8, 2026Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Ascendis Pharma A/S will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Executives will engage in a fireside chat, which will be available via live webcast and for replay on their website. The company emphasizes its focus on innovative therapies using its TransCon technology platform.
Read more →-ASND
Sep 7, 2026Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Ascendis Pharma will present new data from its Endocrinology Rare Disease programs at ESPE 2026 in Marseille. Key highlights include the first cohort data from the pivotal reACHin Trial of TransCon CNP in infants with achondroplasia. The company aims to demonstrate the potential benefits of early intervention in this patient population.
Read more →-ASND
Aug 31, 2026▲ +6.1%on this news
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
Ascendis Pharma has entered a binding term sheet with BioMarin for a global settlement and license agreement concerning YUVIWEL and related products. The agreement resolves all litigation and allows Ascendis to develop and commercialize navepegritide-related products. Ascendis anticipates substantial revenue growth and aims to achieve €5 billion in revenue by 2030.
Read more →-ASND
Aug 25, 2026Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Ascendis Pharma announced an oral presentation of Week 104 data from its pivotal ApproaCH Trial at ISDS 2026. The trial focuses on TransCon CNP (navepegritide) for treating achondroplasia in children. The data indicates significant benefits, including improvements in height and physical functioning, with a favorable safety profile. The FDA has already approved TransCon CNP under the name YUVIWEL.
Read more →-ASND
Aug 13, 2026Ascendis Pharma Reports Second Quarter 2026 Financial Results
Ascendis Pharma reported a significant increase in product revenue for Q2 2026, totaling €315 million, driven by strong sales of YORVIPATH, SKYTROFA, and YUVIWEL. The company highlighted successful trial data presentations and completion of key enrollment milestones. Ascendis also settled its convertible notes and was added to multiple Russell U.S. Indexes, indicating a strong market position.
Read more →-ASND
Aug 6, 2026Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
Ascendis Pharma A/S announced plans to report its second quarter 2026 financial results and provide a business update on August 13, 2026. A conference call will follow the report, allowing investors to engage with the company. The announcement highlights Ascendis' commitment to transparency and innovation in addressing patient needs.
Read more →-ASND
Aug 6, 2026Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Ascendis Pharma announced positive results from the Phase 2 COACH Trial, showing significant growth improvements in children with achondroplasia using TransCon CNP and TransCon hGH combination therapy. The company also reported successful enrollment in the pivotal reACHin Trial for infants and noted a strong uptake of YUVIWEL in the U.S., with over 65% of patients approved for reimbursement.
Read more →-ASND
Jun 30, 2026Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
Ascendis Pharma reported positive results from the ApproaCH Trial, showing that children with achondroplasia treated with TransCon CNP demonstrated sustained improvements in lower extremity alignment over 104 weeks. The trial highlighted significant reductions in tibial-femoral angle, particularly in children with preexisting genu varum. The treatment was well tolerated, with no serious adverse events reported.
Read more →-ASND
Jun 26, 2026Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
Ascendis Pharma A/S has announced its inclusion in several Russell U.S. Indexes, including the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap. This change is effective as of June 26, 2026, and reflects the company's growing market presence. The Russell Indexes are widely utilized by investment managers, indicating potential for increased investment interest.
Read more →-ASND
Jun 25, 2026Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Ascendis Pharma will present new data on treatments for achondroplasia at ICCBH 2026. The presentations include Week 104 data from the pivotal ApproaCH Trial and findings from the COACH Trial. These results highlight the benefits of TransCon CNP and its combination with TransCon hGH, addressing significant unmet needs in affected children.
Read more →-ASND
Jun 13, 2026Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
Ascendis Pharma announced positive results from the Phase 3 PaTHway Trial of TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism over 182 weeks. The treatment replicated the actions of endogenous PTH, leading to significant improvements in kidney function and quality of life. An impressive 89% of patients completed the trial, with no new safety concerns reported.
Read more →-ASND
Jun 8, 2026Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
Ascendis Pharma A/S will present new data on its Endocrinology Rare Disease programs at ENDO 2026 in Chicago. The presentations will cover treatments for hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The company emphasizes the long-term safety and efficacy of its therapies, particularly TransCon PTH and TransCon CNP.
Read more →-ASND
May 7, 2026Ascendis Pharma Reports First Quarter 2026 Financial Results - Q1 2026 revenue of 197 million for YORVIPATH and 44 million for SKYTROFA - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in
Ascendis Pharma A/S reported strong financial results for Q1 2026, achieving a revenue of 197 million for YORVIPATH and 44 million for SKYTROFA. The company noted over 1,000 new patient enrollments for YORVIPATH in the U.S. and a substantial net profit of 629 million, a significant improvement from the previous year's loss. Despite these positive outcomes, there was an increase in total operating and net finance expenses compared to the same quarter last year. Ascendis continues to expand its market presence and innovations in biopharmaceuticals.
Read more →-ASND
May 7, 2026Ascendis Pharma Reports First Quarter 2026 Financial Results
Ascendis Pharma reported strong financial results for Q1 2026, with total revenue reaching €247 million, driven primarily by YORVIPATH. The company also noted significant patient enrollments for both YORVIPATH and YUVIWEL, the latter of which received FDA accelerated approval. Despite increased operating expenses, the overall outlook remains positive as Ascendis continues to expand its market presence.
Read more →-ASND
May 6, 2026New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
Ascendis Pharma announced new data from the ApproaCH Trial, showing that children with achondroplasia aged 5 years and older treated with TransCon CNP exhibited significant annualized growth velocity improvements compared to placebo. The safety profile remained consistent over two years, with mild injection site reactions and no serious adverse effects. These findings reinforce the drug's potential in promoting healthy growth in affected children.
Read more →-ASND
Apr 30, 2026Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
Ascendis Pharma A/S announced it will report its first quarter 2026 financial results and provide a business update on May 7, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day. This event aims to engage investors and share insights on their innovative TransCon technology platform.
Read more →-ASND
Apr 21, 2026Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
Ascendis Pharma A/S has announced the redemption of all $575 million of its outstanding 2.25% Convertible Senior Notes due 2028, effective May 6, 2026. This decision follows the last reported sale price per ordinary share exceeding 130% of the conversion price for a specified period. Holders can convert their notes before the redemption date, with an increased conversion rate during the Make-Whole Conversion Period.
Read more →About Ascendis Pharma A/S
HeadquartersHellerup
Founded2006
BIOPHARMAWATCH ELITE PLUS
Trade the next ASND catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime